Hasil Pencarian - Ana Arance

  • Menampilkan 1 - 13 hasil dari 13
Perbaiki Hasil
  1. 1
    Molecular Markers and Targets in Melanoma

    Molecular Markers and Targets in Melanoma oleh Cristina Teixido, Paola Castillo, Clara Martinez-Vila, Ana Arance, Llucia Alos

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist’s Perspective on Current Knowledge

    Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist’s Perspective on Current Knowledge oleh Clara Martínez-Vila, Europa Azucena González-Navarro, Cristina Teixido, Roberto Martin, Francisco Aya, Manel Juan, Ana Arance

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients

    Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients oleh Paola Castillo, Marta Marginet, Pedro Jares, Mireia García, Elena Gonzalvo, Ana Arance, Adriana García, Llucia Alos, Cristina Teixido

    Diterbitkan 2020-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence

    Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence oleh Sümeyre Seda Ertekin, Sebastian Podlipnik, Constanza Riquelme-Mc Loughlin, Alicia Barreiro-Capurro, Ana Arance, Cristina Carrera, Josep Malvehy, Susana Puig

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Feasibility and Impact of Embedding an Extended DNA and RNA Tissue-Based Sequencing Panel for the Routine Care of Patients with Advanced Melanoma in Spain

    Feasibility and Impact of Embedding an Extended DNA and RNA Tissue-Based Sequencing Panel for the Routine Care of Patients with Advanced Melanoma in Spain oleh Natalia Castrejon, Roberto Martin, Antonio Carrasco, Paola Castillo, Adriana Garcia, Raquel Albero-González, Mireia García, Marta Marginet, Núria Palau, Mónica Hernández, Carla Montironi, Guillem Clot, Ana Arance, Llucia Alos, Cristina Teixido

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain

    Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain oleh Jose A. Lopez-Martin, Ana Arance Fernández, Juan José Ríos-Martín, Javier Hernández-Losa, Lucía Alós Hernández, Pablo Cerezuela Fuentes, Sebastián Ortiz Reina, Eugenia Ortega Izquierdo, Rosa M Martí, Jesús Soberino García, Berta Ferrer Fábrega, José Luis Rodríguez Peralto

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

    Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma oleh Gabriella Liszkay, Catriona McNeil, Michele Maio, Vanna Chiarion-Sileni, Luc Thomas, Andrzej Mackiewicz, Michelle Del Vecchio, Ana Arance, Laurent Mortier, Lars Bastholt, Brigitte Dreno, Marta Nyakas, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Joanna Pikiel, Fareeda Hosein, Burcin Simsek

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series

    Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series oleh Lisa Zimmer, Bastian Schilling, Yinghong Wang, Georgina V Long, Jennifer McQuade, Ana Arance, Douglas B Johnson, Nadia Yousaf, Kazi J Nahar, Matteo S Carlino, Kate Young, Joanna Lee, Liselotte Tas, Serigne N Lo, Christian Blank, Alexander Maxwell Menzies, Catriona Harvey, Janet McKeown, Sheima Farag, Aafke Meerveld-Eggink, Austin Thomas, Roberto Martín Huertas

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

    Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial oleh Maria Gonzalez-Cao, Clara Mayo de las Casas, Juana Oramas, Miguel A. Berciano-Guerrero, Luis de la Cruz, Pablo Cerezuela, Ana Arance, Eva Muñoz-Couselo, Enrique Espinosa, Teresa Puertolas, Roberto Diaz Beveridge, Sebastian Ochenduszko, Maria-Jose Villanueva, Laura Basterretxea, Lorena Bellido, Delvys Rodriguez, Begoña Campos, Clara Montagut, Ana Drozdowskyj, Miguel A. Molina, Jose Antonio Lopez-Martin, Alfonso Berrocal

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

    Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival oleh James Larkin, Jeffrey Weber, Victoria Atkinson, Michael Millward, Ivan Marquez-Rodas, Luis de la Cruz-Merino, Helen Gogas, Paolo A Ascierto, Anna Maria Di Giacomo, Veerle de Pril, Vanna Chiarion-Sileni, Stephane Dalle, Leslie Fecher, Ana Arance, Jean-Jacques Grob, Nikhil I Khushalani, Michele Del Vecchio, Mario Mandala, C Lance Cowey, Michael Schenker, Petr Arenberger, Maurice Lobo

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

    961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1... oleh Caroline Robert, Helena Escuin-Ordinas, Juan Martin-Liberal, Miguel Sanmamed, Stephane Dalle, Ana Arance, Marya Chaney, Sorilla Prey, Alfonso Berrocal, Caroline Dutriaux, Iván Márquez Rodas, Philippe Saiag, Luis de la Cruz Merino, Juan Rodríguez-Moreno, Eduardo Castañón Álvarez, Pablo Cerezuela-Fuentes, Henry Montaudie, María González Cao, Julie Charles, María Pilar López Criado, Enrique de Miguel, Elisa Funk-Brentano, Roberto Huertas, Delvys Rodríguez Abreu, Eva Muñoz Couselo, Javier Sánchez López, Sonia Maciá

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.

    Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study. oleh Iván Márquez-Rodas, Manuel Martín González, Eduardo Nagore, Cristina Gómez-Fernández, Jose Antonio Avilés-Izquierdo, Cayetana Maldonado-Seral, Virtudes Soriano, Margarita Majem-Tarruella, Virginia Palomar, Rocio Maseda, Alfonso Martín-Carnicero, Teresa Puertolas, Elena Godoy, Pablo Cerezuela, Maria Ochoa de Olza, Begoña Campos, Elisabeth Perez-Ruiz, Ainara Soria, Irene Gil-Arnaiz, Maria Gonzalez-Cao, Elisa Galvez, Ana Arance, Joaquin Belon, Luis de la Cruz-Merino, Salvador Martín-Algarra, Spanish Multidisciplinary Group of Melanoma (GEM)

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

    Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial oleh Paolo A. Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: